Table 3. Effect of mycophenolate on pulmonary function.
| Duration of Therapy (months) | Baseline DLCO (% predicted) | DLCO at end of study (% predicted) | Level of significance | Baseline FVC (% predicted) | FVC at end of study (% predicted) | Level of significance | |
|---|---|---|---|---|---|---|---|
| Stratton et al.[19] | 12 | 66 | 63 | Not significant | 87 | 88 | Not significant |
| Vanthuyne et al.[25] | 12 | 63 | 76 | p = 0.0009 | NA | NA | NA |
| Le et al.[31] | 12 | 77.4 | 79.2 | p = 0.336 | 79.4 | 80.7 | p = 0.264 |
| Mendoza et al.[20] | 18.2 | 69 | 70.5 | p = 0.45 | NA | NA | NA |
| Cuomo et al.[36] | 5 | 60 | NA | NA | 104 | NA | NA |
| Saketkoo et al.[37] | 3 | 30 | NA | NA | 80 | NA | NA |
| Zamora et al.[28] | 24 | 50 | NA | p = 0.84 | 72 | NA | p = 0.57 |
| Gerbino et al.[26] | 24 | 51 | NA | p = 0.38 | NA | NA | NA |
| Derk et al.[21] | 12 | 71.2 | 74.3 | Not significant | 99.2 | 105 | Not significant |
| Koutroumpas et al.[29] | 12 | 80.7 | 86.7 | p = 0.66 | 79.5 | 87.1 | p = 0.04 |
| Simeon-Aznar et al.[22] | 12 | 40 | 37 | NA | 64 | 64 | NA |
| Liossis et al.[24] | 4–6 | 64.2 | 75.4 | p = 0.033 | 65.6 | p = 0.057 | |
| Herrick et al.[23] | |||||||
| Protocol 1 | 36 | 58.8 | NA | NA | 76 | NA | NA |
| Protocol 2 | 36 | 76.1 | NA | NA | 93.3 | NA | NA |
| Protocol 3 | 36 | 71.5 | NA | NA | 87.8 | NA | NA |
NA not available, DLCO diffusing capacity of carbon monoxide, FVC functional vital capacity, VC vial capacity, TLC total lung capacity